Brian W Dymock

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3532490/publications.pdf

Version: 2024-02-01

78 papers	4,531 citations	109321 35 h-index	102487 66 g-index
80 all docs	80 docs citations	80 times ranked	5410 citing authors

#	Article	IF	Citations
1	NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis. Cancer Research, 2008, 68, 2850-2860.	0.9	433
2	4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer. Journal of Medicinal Chemistry, 2008, 51, 196-218.	6.4	386
3	Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms. Chemistry and Biology, 2004, 11, 775-785.	6.0	244
4	Novel, Potent Small-Molecule Inhibitors of the Molecular Chaperone Hsp90 Discovered through Structure-Based Design. Journal of Medicinal Chemistry, 2005, 48, 4212-4215.	6.4	232
5	Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23 (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma. Journal of Medicinal Chemistry, 2011, 54, 4638-4658.	6.4	163
6	SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia, 2011, 25, 1751-1759.	7.2	162
7	Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to Orally Active 2-Aminothieno[2,3-d]pyrimidine Inhibitors of the Hsp90 Molecular Chaperone. Journal of Medicinal Chemistry, 2009, 52, 4794-4809.	6.4	157
8	Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Molecular Cancer Therapeutics, 2007, 6, 1198-1211.	4.1	141
9	Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets. Journal of Chemical Information and Computer Sciences, 2004, 44, 2157-2166.	2.8	139
10	TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia, 2012, 26, 236-243.	7.2	110
11	GYY4137, a Novel Water-Soluble, H2S-Releasing Molecule. Methods in Enzymology, 2015, 554, 143-167.	1.0	84
12	3-(5-chloro-2,4-dihydroxyphenyl)-Pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 5197-5201.	2.2	83
13	Discovery of (2E)-3-{2-Butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile. Journal of Medicinal Chemistry, 2011, 54, 4694-4720.	6.4	82
14	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat. Journal of Medicinal Chemistry, 2017, 60, 8336-8357.	6.4	82
15	A fluorescence polarization assay for inhibitors of Hsp90. Analytical Biochemistry, 2006, 350, 202-213.	2.4	81
16	4-Amino derivatives of the Hsp90 inhibitor CCT018159. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2543-2548.	2.2	79
17	Hydrogen Sulfide Is an Endogenous Regulator of Aging in Caenorhabditis elegans. Antioxidants and Redox Signaling, 2014, 20, 2621-2630.	5.4	79
18	Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines. Journal of Medicinal Chemistry, 2016, 59, 8233-8262.	6.4	78

#	Article	IF	Citations
19	Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-deca (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer. Journal of Medicinal Chemistry, 2012, 55, 169-196.	6.4	77
20	Discovery of New H₂S Releasing Phosphordithioates and 2,3-Dihydro-2-phenyl-2-sulfanylenebenzo[d][1,3,2]oxazaphospholes with Improved Antiproliferative Activity. Journal of Medicinal Chemistry, 2015, 58, 6456-6480.	6.4	71
21	DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 894-899.	2.2	70
22	Adenine derived inhibitors of the molecular chaperone HSP90â€"SAR explained through multiple X-ray structures. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 325-328.	2.2	69
23	Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality. Nature Communications, 2017, 8, 2200.	12.8	63
24	Novel Approaches to the Treatment of Hepatitis C Virus Infection. Antiviral Chemistry and Chemotherapy, 2000, 11, 79-86.	0.6	62
25	VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer. Molecular Cancer Therapeutics, 2013, 12, 151-161.	4.1	59
26	Emerging therapies for hepatitis C virus infection. Expert Opinion on Emerging Drugs, 2001, 6, 13-42.	1.1	58
27	Hydrogen Sulfide Promotes Adipogenesis in 3T3L1 Cells. PLoS ONE, 2015, 10, e0119511.	2.5	56
28	New patented histone deacetylase inhibitors. Expert Opinion on Therapeutic Patents, 2009, 19, 1727-1757.	5.0	55
29	Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 â€" 2012. Expert Opinion on Therapeutic Patents, 2013, 23, 449-501.	5.0	51
30	A novel slow-releasing hydrogen sulfide donor, FW1256, exerts anti-inflammatory effects in mouse macrophages and in vivo. Pharmacological Research, 2016, 113, 533-546.	7.1	51
31	Identification of a novel class of orally active pyrimido[5,4-3][1,2,4]triazine-5,7-diamine-based hypoglycemic agents with protein tyrosine phosphatase inhibitory activity. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2895-2898.	2.2	48
32	Inhibitors of HSP90 and other chaperones for the treatment of cancer. Expert Opinion on Therapeutic Patents, 2004, 14, 837-847.	5.0	46
33	Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(20), (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis. Journal of Medicinal Chemistry, 2012, 55, 2623-2640.	6.4	41
34	3-(Trimethylsilyl)oxetan-2-ones via enantioselective [2 + 2] cycloaddition of (trimethylsilyl)ketene to aldehydes catalysed by methylaluminiomidazolines. Chemical Communications, 1996, , 1053.	4.1	40
35	A Synthesis of the Hypocholesterolemic Agent 1233A Via Asymmetric [2 + 2] Cycloaddition. Synthesis, 1998, 1998, 1655-1661.	2.3	37
36	Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors. Molecular Cancer Therapeutics, 2006, 5, 1628-1637.	4.1	37

#	Article	IF	Citations
37	Antioxidants inhibit neuronal toxicity in Parkinson's diseaseâ€linked LRRK 2. Annals of Clinical and Translational Neurology, 2016, 3, 288-294.	3.7	36
38	Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3). Journal of Computer-Aided Molecular Design, 2012, 26, 437-450.	2.9	33
39	Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat. European Journal of Medicinal Chemistry, 2018, 158, 593-619.	5.5	33
40	Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3). Journal of Molecular Modeling, 2013, 19, 119-130.	1.8	32
41	Selective JAK inhibitors. Future Medicinal Chemistry, 2014, 6, 1439-1471.	2.3	32
42	Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1725-1729.	2.2	31
43	SB1578, a Novel Inhibitor of JAK2, FLT3, and c-Fms for the Treatment of Rheumatoid Arthritis. Journal of Immunology, 2012, 189, 4123-4134.	0.8	31
44	Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	25
45	Intracellular Hyper-Acidification Potentiated by Hydrogen Sulfide Mediates Invasive and Therapy Resistant Cancer Cell Death. Frontiers in Pharmacology, 2017, 8, 763.	3.5	25
46	The Squalestatins:Â Decarboxy and 4-Deoxy Analogues as Potent Squalene Synthase Inhibitors1. Journal of Medicinal Chemistry, 1996, 39, 207-216.	6.4	24
47	Structure and Ligand-Based Design of mTOR and PI3-Kinase Inhibitors Leading to the Clinical Candidates VS-5584 (SB2343) and SB2602. Journal of Chemical Information and Modeling, 2014, 54, 3238-3250.	5.4	24
48	Predicting chemotherapeutic drug combinations through gene network profiling. Scientific Reports, 2016, 6, 18658.	3.3	24
49	Recently discovered EZH2 and EHMT2 (G9a) inhibitors. Future Medicinal Chemistry, 2016, 8, 1635-1654.	2.3	24
50	The Squalestatins: Novel Inhibitors of Squalene Synthase. Enzyme Inhibitory Activities and in vivo Evaluation of C1-Modified Analogs. Journal of Medicinal Chemistry, 1994, 37, 3274-3281.	6.4	22
51	Mutation of histone H3 serine 86 disrupts GATA factor Ams2 expression and precise chromosome segregation in fission yeast. Scientific Reports, 2015, 5, 14064.	3.3	21
52	Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (HSP90). Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1357-1362.	2.2	21
53	Fragment-Based Whole Cell Screen Delivers Hits against M. tuberculosis and Non-tuberculous Mycobacteria. Frontiers in Microbiology, 2016, 7, 1392.	3.5	20
54	A Small Molecule Targeting the Transmembrane Domain of Death Receptor p75NTR Induces Melanoma Cell Death and Reduces Tumor Growth. Cell Chemical Biology, 2018, 25, 1485-1494.e5.	5.2	20

#	Article	IF	Citations
55	Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome. Frontiers in Microbiology, 2017, 8, 746.	3.5	19
56	SAHA and cisplatin sensitize gastric cancer cells to doxorubicin by induction of DNA damage, apoptosis and perturbation of AMPK-mTOR signalling. Experimental Cell Research, 2018, 370, 283-291.	2.6	18
57	Hydrocarbon stapled B chain analogues of relaxin-3 retain biological activity. Peptides, 2016, 84, 44-57.	2.4	17
58	Structure-based optimization of morpholino-triazines as PI3K and mTOR inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1009-1013.	2.2	16
59	Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6). Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2636-2640.	2.2	15
60	Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor. European Journal of Medicinal Chemistry, 2019, 184, 111755.	5.5	15
61	Intranasal administration of a stapled relaxinâ€3 mimetic has anxiolyticâ€and antidepressantâ€like activity in rats. British Journal of Pharmacology, 2019, 176, 3899-3923.	5.4	15
62	The Squalestatins: Synthesis and Biological Activity of Some C3-Modified Analogs; Replacement of a Carboxylic Acid or Methyl Ester with an Isoelectronic Heterocyclic Functionality. Journal of Medicinal Chemistry, 1995, 38, 3502-3513.	6.4	14
63	Overcoming chloroquine resistance in malaria: Design, synthesis and structureâ€“activity relationships of novel chemoreversal agents. European Journal of Medicinal Chemistry, 2016, 119, 231-249.	5.5	14
64	Discovery of the cancer cell selective dual acting anti-cancer agent (Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitrile (A131). European Journal of Medicinal Chemistry, 2018, 156, 344-367.	5.5	12
65	Structure-based design of PDK1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 305-307.	2.2	11
66	Overcoming Chloroquine Resistance in Malaria: Design, Synthesis, and Structure-Activity Relationships of Novel Hybrid Compounds. Antimicrobial Agents and Chemotherapy, 2016, 60, 3076-3089.	3.2	11
67	2-Anilino-4-aryl-8H-purine derivatives as inhibitors of PDK1. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2880-2884.	2.2	9
68	Discovery of medium ring thiophosphorus based heterocycles as antiproliferative agents. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 967-972.	2.2	9
69	Fluorescent Probes for H2S Detection and Quantification. Handbook of Experimental Pharmacology, 2015, 230, 291-323.	1.8	9
70	Thieno[3,2-d]pyrimidin-4(3H)-one derivatives as PDK1 inhibitors discovered by fragment-based screening. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4023-4027.	2.2	8
71	Analysis of Protein Target Interactions of Synthetic Mixtures by Affinity-LC/MS. SLAS Discovery, 2017, 22, 440-446.	2.7	8
72	SB1518: A Potent and Orally Active JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders.. Blood, 2007, 110, 538-538.	1.4	8

#	Article	IF	Citations
73	Novel squalestatin derivatives arising from reactions at the allylic centre of the C1-side chain. Journal of the Chemical Society Perkin Transactions 1, 1998, , 327-334.	0.9	6
74	The rise of epigenetic drug discovery. Future Medicinal Chemistry, 2016, 8, 1523-1524.	2.3	5
75	Prodrugs of the cancer cell selective anti-cancer agent (Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitrile (A131) are orally efficacious in a mouse model of resistant colon cancer. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 216-219.	2.2	3
76	SB1317, a Potent and Orally Active FLT3-CDK Inhibitor with High Anti-Tumor Efficacy in Models of Hematological Malignancies.. Blood, 2007, 110, 1593-1593.	1.4	2
77	CHAPTER 5. Small Molecule Macrocyclic Kinase Inhibitors. RSC Drug Discovery Series, 2018, , 97-127.	0.3	2
78	Adenine Derived Inhibitors of the Molecular Chaperone HSP90â€"SAR Explained Through Multiple X-Ray Structures.. ChemInform, 2004, 35, no.	0.0	0